Alexander M M Eggermont Selected Research

Melphalan (Alkeran)

2/2015	Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
6/2013	The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
5/2012	Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
2/2012	20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.
10/2011	Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
2/2011	Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
1/2009	Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities.
12/2007	Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.
4/2007	Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.
2/2007	Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander M M Eggermont Research Topics

Disease

132	Melanoma (Melanoma, Malignant) 11/2022 - 03/2002
114	Neoplasms (Cancer) 01/2022 - 01/2002
39	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2003
26	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2002
11	Hyperthermia 01/2021 - 04/2010
9	Necrosis 02/2015 - 05/2003
7	Lymphatic Metastasis 11/2020 - 10/2005
6	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2003
6	Rectal Neoplasms (Rectal Cancer) 03/2013 - 05/2005
5	Renal Cell Carcinoma (Grawitz Tumor) 10/2016 - 02/2003
3	COVID-19 01/2022 - 01/2021
3	Margins of Excision 05/2015 - 08/2002
3	Fatigue 01/2015 - 10/2009
3	Osteosarcoma (Osteogenic Sarcoma) 07/2005 - 01/2002
2	Disease Progression 01/2021 - 06/2011
2	Diarrhea 06/2011 - 01/2002
2	Hemorrhage 09/2006 - 05/2003
2	Edema (Dropsy) 07/2005 - 05/2005
1	Pneumonia (Pneumonitis) 01/2022
1	Squamous Cell Carcinoma of Head and Neck 01/2021
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2020
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2020

Drug/Important Bio-Agent (IBA)

34	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2014 - 01/2002
32	Pharmaceutical PreparationsIBA 01/2018 - 07/2003
24	Melphalan (Alkeran)FDA LinkGeneric 02/2015 - 01/2003
20	Liposomes (Liposome)IBA 01/2018 - 01/2002
18	InterferonsIBA 01/2018 - 10/2002
14	IpilimumabIBA 01/2022 - 10/2010
14	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 01/2002
13	pembrolizumabIBA 01/2022 - 11/2017
11	Interferon-alpha (Interferon Alfa)IBA 07/2013 - 10/2002
10	CytokinesIBA 07/2013 - 10/2002
9	Immune Checkpoint InhibitorsIBA 01/2022 - 06/2015
9	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2002
9	Biological ProductsIBA 01/2019 - 08/2005
9	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2013
6	Dacarbazine (DIC)FDA LinkGeneric 03/2014 - 08/2004
5	VaccinesIBA 01/2022 - 02/2005
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 01/2012
5	AntibodiesIBA 01/2018 - 06/2009
5	Monoclonal AntibodiesIBA 01/2016 - 10/2010
5	Interleukin-2 (IL2)IBA 04/2011 - 05/2005
4	NivolumabIBA 01/2022 - 06/2015
4	dabrafenibIBA 01/2022 - 01/2015
4	AntigensIBA 01/2018 - 07/2013
4	LipidsIBA 03/2016 - 08/2010
4	liposomal doxorubicin (Doxil)FDA Link 03/2016 - 01/2002
4	SphingolipidsIBA 08/2015 - 01/2011
4	Messenger RNA (mRNA)IBA 07/2013 - 05/2005
4	Monophenol Monooxygenase (Tyrosinase)IBA 12/2010 - 07/2003
4	Histamine (Histamine Dihydrochloride)FDA Link 04/2007 - 11/2004
3	Dihydrotachysterol (AT 10)IBA 11/2022 - 03/2016
3	trametinibIBA 01/2022 - 11/2017
3	ParaffinIBA 01/2013 - 12/2010
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2010 - 12/2008
3	Interferon alpha-2 (Roferon-A)FDA Link 05/2010 - 10/2005
3	Cisplatin (Platino)FDA LinkGeneric 07/2009 - 03/2005
3	salicylhydroxamic acid (SHAM)IBA 02/2007 - 05/2005
3	member 1 small inducible cytokine subfamily EIBA 12/2006 - 09/2006
2	COVID-19 VaccinesIBA 01/2021 - 01/2021
2	B7-H1 AntigenIBA 11/2020 - 10/2016
2	Interferon-alpha2bIBA 01/2020 - 07/2004
2	LigandsIBA 05/2018 - 09/2011
2	saponin QA-21V1 (QS21)IBA 01/2018 - 10/2013
2	G(M2) Ganglioside (Ganglioside GM2)IBA 01/2018 - 10/2013
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2017 - 07/2009
2	Tissue Inhibitor of Metalloproteinase-3IBA 10/2016 - 01/2014
2	ChromatinIBA 10/2016 - 04/2014
2	Conditioned Culture MediaIBA 01/2016 - 01/2014
2	Mitoxantrone (Novantrone)FDA LinkGeneric 08/2015 - 04/2015
2	VemurafenibIBA 01/2015 - 06/2011
2	fotemustine (Muphoran)IBA 03/2014 - 10/2005
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 07/2013 - 11/2005
2	Cadherins (E-Cadherin)IBA 11/2012 - 05/2010
2	MART-1 AntigenIBA 12/2010 - 12/2009
2	AutoantibodiesIBA 05/2010 - 06/2009
2	Monoamine Oxidase (MAO)IBA 10/2009 - 01/2005
2	Peptides (Polypeptides)IBA 11/2005 - 07/2003
2	NeopterinIBA 07/2004 - 07/2003
2	Amino Acids FDA Link 07/2004 - 07/2003
2	Neutral Amino AcidsIBA 07/2004 - 07/2003
2	BiopterinsIBA 07/2004 - 07/2003
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	Cancer VaccinesIBA 01/2022
1	Insulin (Novolin)FDA Link 01/2020

Therapy/Procedure

82	Therapeutics 01/2022 - 01/2002
25	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
23	Immunotherapy 01/2022 - 08/2002
14	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 08/2002
9	Surgical Amputation (Amputations) 10/2011 - 01/2003
6	Radiotherapy 01/2013 - 05/2005
5	Neoadjuvant Therapy 01/2018 - 10/2011
3	Limb Salvage 02/2006 - 01/2003
2	Induced Hyperthermia (Thermotherapy) 01/2016 - 04/2013
2	Immunomodulation 03/2014 - 09/2011
2	Adjuvant Radiotherapy 05/2012 - 02/2011
2	Injections 10/2007 - 07/2005
1	Adjuvant Chemotherapy 01/2021
1	Biological Therapy 01/2021
1	Retreatment 01/2021